AAPL339.84-3.11 (-0.91%) ▼|ABBV290.72+8.04 (+2.85%) ▲|ABT102.61-1.46 (-1.40%) ▼|ACN238.96+2.03 (+0.86%) ▲|ADBE255.26+8.17 (+3.30%) ▲|AMAT406.46-6.65 (-1.61%) ▼|AMD542.18+4.13 (+0.77%) ▲|AMGN434.83+9.89 (+2.33%) ▲|AMT184.65+1.62 (+0.88%) ▲|AMZN263.10+0.65 (+0.25%) ▲|AVGO335.28+0.69 (+0.21%) ▲|AXP319.86+3.45 (+1.09%) ▲|BA191.31-0.12 (-0.06%) ▼|BAC50.80+0.41 (+0.81%) ▲|BKNG164.47+1.87 (+1.15%) ▲|BLK1,129.24+4.64 (+0.41%) ▲|BMY61.60+2.77 (+4.71%) ▲|BNY144.36+1.92 (+1.35%) ▲|BRK-B537.93+5.70 (+1.07%) ▲|C122.39+0.70 (+0.58%) ▲|CAT726.45+0.66 (+0.09%) ▲|CL94.02+1.16 (+1.24%) ▲|CMCSA22.21+0.31 (+1.39%) ▲|COF201.93+2.10 (+1.05%) ▲|COP145.84+0.60 (+0.41%) ▲|COST995.38-0.15 (-0.02%) ▼|CRM242.07-0.39 (-0.16%) ▼|CSCO106.63+0.13 (+0.12%) ▲|CVS94.11+1.43 (+1.54%) ▲|CVX224.76+0.39 (+0.17%) ▲|DE636.27+9.27 (+1.48%) ▲|DHR225.45+1.02 (+0.45%) ▲|DIS111.60+2.01 (+1.83%) ▲|DUK121.25+1.98 (+1.66%) ▲|EMR159.79-0.76 (-0.47%) ▼|FDX300.57+6.79 (+2.31%) ▲|GD344.41+2.98 (+0.87%) ▲|GE299.48-11.80 (-3.79%) ▼|GEV896.82-11.62 (-1.28%) ▼|GILD156.32+3.25 (+2.12%) ▲|GM75.90-6.86 (-8.28%) ▼|GOOG336.78-3.38 (-0.99%) ▼|GOOGL340.69-3.49 (-1.01%) ▼|GS885.74+9.96 (+1.14%) ▲|HD315.78+5.90 (+1.90%) ▲|HON212.18+2.20 (+1.05%) ▲|IBM240.33+3.94 (+1.67%) ▲|INTC92.54+0.51 (+0.55%) ▲|INTU336.52+10.90 (+3.35%) ▲|ISRG438.78+5.60 (+1.29%) ▲|JNJ259.72+5.93 (+2.34%) ▲|JPM335.76+2.23 (+0.67%) ▲|KO92.75-0.68 (-0.72%) ▼|LIN499.70-3.75 (-0.74%) ▼|LLY1,292.02+51.68 (+4.17%) ▲|LMT549.29+1.06 (+0.19%) ▲|LOW199.33+3.41 (+1.74%) ▲|LRCX265.14-7.06 (-2.59%) ▼|MA622.00+5.60 (+0.91%) ▲|MCD245.62+2.95 (+1.21%) ▲|MDLZ63.87+0.53 (+0.83%) ▲|MDT94.57+1.80 (+1.94%) ▲|META690.14-15.30 (-2.17%) ▼|MMM171.17+9.16 (+5.65%) ▲|MO74.43+0.34 (+0.46%) ▲|MRK148.25+4.62 (+3.22%) ▲|MS180.42+1.95 (+1.09%) ▲|MSFT532.48-1.04 (-0.19%) ▼|MU909.62+4.72 (+0.52%) ▲|NEE78.83+0.66 (+0.84%) ▲|NFLX69.29-0.56 (-0.80%) ▼|NKE37.95+0.74 (+1.98%) ▲|NOW149.61+4.25 (+2.92%) ▲|NVDA217.09+0.00 (+0.00%) ▲|ORCL131.78+2.19 (+1.69%) ▲|PEP134.26+0.69 (+0.52%) ▲|PFE30.24+0.80 (+2.70%) ▲|PG158.22+0.53 (+0.33%) ▲|PLTR195.76+1.61 (+0.83%) ▲|PM200.05-1.00 (-0.50%) ▼|QCOM176.25+2.72 (+1.57%) ▲|RTX191.57-0.55 (-0.28%) ▼|SBUX99.44+1.57 (+1.60%) ▲|SCHW90.69+1.11 (+1.24%) ▲|SO90.80+1.53 (+1.71%) ▲|SPG205.95+3.46 (+1.71%) ▲|T23.55+0.35 (+1.49%) ▲|TMO690.26+10.88 (+1.60%) ▲|TMUS157.96+1.87 (+1.20%) ▲|TSLA374.66+6.60 (+1.79%) ▲|TXN279.33+3.18 (+1.15%) ▲|UBER69.00-0.96 (-1.37%) ▼|UNH420.66+13.78 (+3.39%) ▲|UNP288.10+1.09 (+0.38%) ▲|UPS99.00+1.54 (+1.58%) ▲|USB58.91+1.06 (+1.83%) ▲|V407.29+4.37 (+1.08%) ▲|VZ44.56+0.41 (+0.92%) ▲|WFC81.64-0.17 (-0.20%) ▼|WMT118.35-0.35 (-0.29%) ▼|XOM177.16-1.12 (-0.63%) ▼|AAPL339.84-3.11 (-0.91%) ▼|ABBV290.72+8.04 (+2.85%) ▲|ABT102.61-1.46 (-1.40%) ▼|ACN238.96+2.03 (+0.86%) ▲|ADBE255.26+8.17 (+3.30%) ▲|AMAT406.46-6.65 (-1.61%) ▼|AMD542.18+4.13 (+0.77%) ▲|AMGN434.83+9.89 (+2.33%) ▲|AMT184.65+1.62 (+0.88%) ▲|AMZN263.10+0.65 (+0.25%) ▲|AVGO335.28+0.69 (+0.21%) ▲|AXP319.86+3.45 (+1.09%) ▲|BA191.31-0.12 (-0.06%) ▼|BAC50.80+0.41 (+0.81%) ▲|BKNG164.47+1.87 (+1.15%) ▲|BLK1,129.24+4.64 (+0.41%) ▲|BMY61.60+2.77 (+4.71%) ▲|BNY144.36+1.92 (+1.35%) ▲|BRK-B537.93+5.70 (+1.07%) ▲|C122.39+0.70 (+0.58%) ▲|CAT726.45+0.66 (+0.09%) ▲|CL94.02+1.16 (+1.24%) ▲|CMCSA22.21+0.31 (+1.39%) ▲|COF201.93+2.10 (+1.05%) ▲|COP145.84+0.60 (+0.41%) ▲|COST995.38-0.15 (-0.02%) ▼|CRM242.07-0.39 (-0.16%) ▼|CSCO106.63+0.13 (+0.12%) ▲|CVS94.11+1.43 (+1.54%) ▲|CVX224.76+0.39 (+0.17%) ▲|DE636.27+9.27 (+1.48%) ▲|DHR225.45+1.02 (+0.45%) ▲|DIS111.60+2.01 (+1.83%) ▲|DUK121.25+1.98 (+1.66%) ▲|EMR159.79-0.76 (-0.47%) ▼|FDX300.57+6.79 (+2.31%) ▲|GD344.41+2.98 (+0.87%) ▲|GE299.48-11.80 (-3.79%) ▼|GEV896.82-11.62 (-1.28%) ▼|GILD156.32+3.25 (+2.12%) ▲|GM75.90-6.86 (-8.28%) ▼|GOOG336.78-3.38 (-0.99%) ▼|GOOGL340.69-3.49 (-1.01%) ▼|GS885.74+9.96 (+1.14%) ▲|HD315.78+5.90 (+1.90%) ▲|HON212.18+2.20 (+1.05%) ▲|IBM240.33+3.94 (+1.67%) ▲|INTC92.54+0.51 (+0.55%) ▲|INTU336.52+10.90 (+3.35%) ▲|ISRG438.78+5.60 (+1.29%) ▲|JNJ259.72+5.93 (+2.34%) ▲|JPM335.76+2.23 (+0.67%) ▲|KO92.75-0.68 (-0.72%) ▼|LIN499.70-3.75 (-0.74%) ▼|LLY1,292.02+51.68 (+4.17%) ▲|LMT549.29+1.06 (+0.19%) ▲|LOW199.33+3.41 (+1.74%) ▲|LRCX265.14-7.06 (-2.59%) ▼|MA622.00+5.60 (+0.91%) ▲|MCD245.62+2.95 (+1.21%) ▲|MDLZ63.87+0.53 (+0.83%) ▲|MDT94.57+1.80 (+1.94%) ▲|META690.14-15.30 (-2.17%) ▼|MMM171.17+9.16 (+5.65%) ▲|MO74.43+0.34 (+0.46%) ▲|MRK148.25+4.62 (+3.22%) ▲|MS180.42+1.95 (+1.09%) ▲|MSFT532.48-1.04 (-0.19%) ▼|MU909.62+4.72 (+0.52%) ▲|NEE78.83+0.66 (+0.84%) ▲|NFLX69.29-0.56 (-0.80%) ▼|NKE37.95+0.74 (+1.98%) ▲|NOW149.61+4.25 (+2.92%) ▲|NVDA217.09+0.00 (+0.00%) ▲|ORCL131.78+2.19 (+1.69%) ▲|PEP134.26+0.69 (+0.52%) ▲|PFE30.24+0.80 (+2.70%) ▲|PG158.22+0.53 (+0.33%) ▲|PLTR195.76+1.61 (+0.83%) ▲|PM200.05-1.00 (-0.50%) ▼|QCOM176.25+2.72 (+1.57%) ▲|RTX191.57-0.55 (-0.28%) ▼|SBUX99.44+1.57 (+1.60%) ▲|SCHW90.69+1.11 (+1.24%) ▲|SO90.80+1.53 (+1.71%) ▲|SPG205.95+3.46 (+1.71%) ▲|T23.55+0.35 (+1.49%) ▲|TMO690.26+10.88 (+1.60%) ▲|TMUS157.96+1.87 (+1.20%) ▲|TSLA374.66+6.60 (+1.79%) ▲|TXN279.33+3.18 (+1.15%) ▲|UBER69.00-0.96 (-1.37%) ▼|UNH420.66+13.78 (+3.39%) ▲|UNP288.10+1.09 (+0.38%) ▲|UPS99.00+1.54 (+1.58%) ▲|USB58.91+1.06 (+1.83%) ▲|V407.29+4.37 (+1.08%) ▲|VZ44.56+0.41 (+0.92%) ▲|WFC81.64-0.17 (-0.20%) ▼|WMT118.35-0.35 (-0.29%) ▼|XOM177.16-1.12 (-0.63%) ▼|
20.2 C
New York
Tuesday, October 20, 2026

Tag: percentage

newsFORsourcecompanycontentinformation1releasesmarket

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology...

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2...

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Tradr to Ring Opening Bell at Cboe to Celebrate SpaceX ETF Launches

Tradr ETFs will ring Cboe's Opening Bell on June 15 to celebrate the launch of SPCM and SPCG, ETFs providing 200% leveraged long and...

Ruvi AI (RUVI) Announces Phase 3 Has Reached 90% Sellout as Investors Race to Secure Remaining Tokens at $0.02

DUBAI, United Arab Emirates, June 14, 2026 (GLOBE NEWSWIRE) -- Ruvi AI, the AI-powered blockchain ecosystem combining artificial intelligence, decentralized infrastructure, creator monetization, and tokenized participation, has announced that Phase 3 of its ongoing token presale has now reached 90% completion.

MSFT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Microsoft Corporation and Announces Opportunity for Investors with Substantial Losses...

The case alleges Microsoft and certain of its top executives made false and/or misleading statements to investors.

Gencor Releases Second Quarter Fiscal 2026 Results

ORLANDO, Fla., June 12, 2026 (GLOBE NEWSWIRE) -- Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the quarter ended March 31, 2026 was $33,799,000 compared with $38,204,000 net revenue for the quarter ended March 31, 2025. The decrease in net revenue was primarily due to lower contract equipment revenues recognized over time and associated freight revenue, which resulted from the timing of orders and shipments. As a percentage of net revenue, gross profit margins increased 200 basis points to 31.7% in the quarter ended March 31, 2026, compared to 29.7% in the quarter ended March 31, 2025.

GraniteShares Announces Forward Splits

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) -- This announcement amends the effective date (or ex-date) previously circulated on June 08, 2026.

Coffee Holding Company Reports Second Quarter Results.

STATEN ISLAND, New York, June 12, 2026 (GLOBE NEWSWIRE) -- Coffee Holding Co., Inc. (Nasdaq: JVA) (the “Company,” “our” or “we”) announced its operating results for the fiscal quarter ended April 30, 2026.

SHPT Unveils M5 & P5 Series: A New Cutting-edge Solution to Accelerate Large-Scale Hydrogen Energy Adoption

SHANGHAI, June 12, 2026 /PRNewswire/ -- On June 10, 2026, SHPT held its "New Core, New Journey" New Product Launch during the 10th International Hydrogen...

Martello Reports Financial Results for the Fourth Quarter and 2026 Fiscal Year

Positive adjusted EBITDA in Q4 marks a significant milestone, positioning the Company for sustained profitable growth driven by innovation for partners and enterprises.Adjusted EBITDA...

Hiding in Plain Sight: New Survey Exposes Awareness Gap Around the Second Most Common Type of Breast Cancer

Hiding in Plain Sight: New Survey Exposes Awareness Gap Around the Second Most Common Type of Breast Cancer

NEMESIA SARL ANNOUNCES RECEIPT OF DISTRIBUTION IN KIND OF SHARES OF LunR ROYALTIES CORP. FROM LUNDIN GOLD INC.

LUXEMBOURG, June 11, 2026 /CNW/ - Nemesia S.à.r.l, ("Nemesia"), a company controlled by trusts settled by the late Adolf H. Lundin of 42, Boulevard...

Victoria’s Secret & Co. Shareholders Decisively Re-Elect All Nine Company Director Nominees

Outcome reflects strong shareholder support for full Board, Company’s Path to Potential strategy and continued momentum under CEO Hillary Super

Defiance ETFs to Launch SPCU, The 2X SpaceX ETF, as the SpaceX (SPCX) IPO Nears

Defiance ETFs to Launch SPCU, The 2X SpaceX ETF, as the SpaceX (SPCX) IPO Nears

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPercentage

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers